Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like Dads should be screened for postpartum depression, study suggests October 5, 2023 Impact of Cannabis Act: Increase in cannabis disorders among pregnant women in Quebec June 24, 2024 Researchers evaluate possible mitochondrial factors in Alzheimer’s pathogenesis December 5, 2023